| |
Presco Study, Interim Results: Pegasys + Weight-Based Ribavirin Suggest Similar SVR Rates as n HCV-Monoinfected Patients
|
| |
| |
Reported by Jules Levin
The interim end-of-treatment response rates in the PRESCO Study were reported at last years 1st Coinfection Workshop. The first slide shows the percent of patients who develop advanced stage HCV in the European Collaborative Study.
The APRICOT and RIBAVIC studies used fixed ribavirin dose of 800 mg daily, and ACTG A5071 started with 600 mg daily for 4 weeks, dosed up to 800 mg for the next 4 weeks, then 1000 mg until the end of treatment. PRESCO uses 1000 mg of ribavirin daily for people weighing less than 75 kg and 1200 mg for people weighing more. The study enrollees were selected & an easier group to treat, but the interim results suggest that response rates can be improved in coinfected patients. All enrollees started the study with a CD4+ cell count above 300 cells/mm3 and take 180 ƒÊg of peginterferon alfa-2a weekly.
|
|
| |
| |
|
|
|
